Eli Lilly and Company and Takeda Pharmaceutical Company Limited: A Comprehensive Revenue Analysis

Pharma Giants' Revenue Growth: Eli Lilly vs. Takeda

__timestampEli Lilly and CompanyTakeda Pharmaceutical Company Limited
Wednesday, January 1, 2014196156000001777824000000
Thursday, January 1, 2015199587000001807378000000
Friday, January 1, 2016212221000001732051000000
Sunday, January 1, 2017228713000001770531000000
Monday, January 1, 2018214933000002097224000000
Tuesday, January 1, 2019223195000003291188000000
Wednesday, January 1, 2020245398000003197812000000
Friday, January 1, 2021283184000003569006000000
Saturday, January 1, 2022285414000004027478000000
Sunday, January 1, 2023341241000004263762000000
Monday, January 1, 2024450427000004263762000000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Pharmaceutical Giants: Eli Lilly and Takeda

In the ever-evolving landscape of the pharmaceutical industry, Eli Lilly and Company and Takeda Pharmaceutical Company Limited stand as titans. Over the past decade, these companies have demonstrated remarkable growth, with Takeda's revenue soaring by approximately 140% from 2014 to 2023. Meanwhile, Eli Lilly has seen a steady increase of around 74% in the same period.

Revenue Trends and Insights

Eli Lilly's revenue journey began at $19.6 billion in 2014, reaching a peak of $34.1 billion by 2023. Takeda, on the other hand, started with a staggering $1.78 trillion in 2014, climbing to an impressive $4.26 trillion in 2023. This growth reflects their strategic expansions and innovations in the pharmaceutical sector. However, it's worth noting that Eli Lilly's data for 2024 is currently unavailable, leaving room for speculation on future trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025